Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
One of the biggest barriers to GLP-1 medications is cost. Without insurance coverage, these drugs can run $800-$1,100 per month. Here’s a comprehensive breakdown of insurance coverage for the most popular GLP-1 medications.
Insurance Coverage By Medication
Ozempic (Semaglutide for Diabetes)
Ozempic typically has the best insurance coverage because it’s approved for type 2 diabetes — a condition most insurance plans cover. If you have a type 2 diabetes diagnosis, there’s a good chance your insurance will cover Ozempic with a copay of $25-$50/month after meeting your deductible.
Wegovy (Semaglutide for Weight Loss)
Coverage for Wegovy is much more limited. Many commercial insurance plans and most Medicare/Medicaid plans do not cover weight loss medications. However, this is slowly changing. As of 2024, some Medicare Advantage plans have begun covering Wegovy for patients with cardiovascular disease following new FDA approvals.
Mounjaro/Zepbound (Tirzepatide)
Mounjaro (for diabetes) typically has decent insurance coverage. Zepbound (for obesity) has better coverage than Wegovy due to it being newer and having stronger clinical data, but still varies widely by plan.
How to Maximize Your Coverage
- Check your formulary — Call your insurance or check online to see if your specific drug is covered
- Prior authorization — Many plans require documentation of failed weight loss attempts
- Manufacturer savings cards — Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound) offer savings programs for eligible commercially insured patients
- Telehealth providers — Some online providers work specifically with GLP-1 medications and can navigate insurance for you
What If You Don’t Have Coverage?
If your insurance doesn’t cover these medications, consider manufacturer patient assistance programs. Novo Nordisk and Eli Lilly both have programs for uninsured or underinsured patients. Additionally, compounded semaglutide has been available from some pharmacies at lower costs, though this option comes with important regulatory caveats.
Insurance plans vary widely. Always verify coverage with your specific insurance provider and pharmacy.
GLP-1 Insurance Coverage by Plan Type in 2026
| Plan Type | Ozempic (T2D) | Wegovy (Obesity) | Mounjaro (T2D) | Zepbound (Obesity) |
|---|---|---|---|---|
| Commercial (Employer) | Usually covered | Varies — improving | Usually covered | Varies — improving |
| Medicare Part D | Covered (T2D) | Covered (CV disease only) | Covered (T2D) | Limited |
| Medicaid | Most states cover | State-by-state | Most states cover | Limited |
| ACA Marketplace | Covered if T2D | Rarely covered | Covered if T2D | Rarely covered |
| No Insurance | ~$968/mo list | ~$1,349/mo list | ~$1,069/mo list | ~$1,059/mo list |
Why Insurance Covers Ozempic But Not Always Wegovy
The distinction is simple but maddening: obesity is not always treated as a medical condition by insurers. Ozempic is approved for Type 2 diabetes — a condition nearly all insurers cover. Wegovy is approved for weight management — which many insurers historically excluded as “lifestyle” or “cosmetic.”
This is changing. The 2024 SELECT trial proved Wegovy reduces major cardiovascular events by 20% in non-diabetic obese patients — a hard clinical outcome. Medicare now covers Wegovy for patients with obesity + established cardiovascular disease. Many commercial insurers followed suit in 2025.
How to Get GLP-1 Medications Covered: Step by Step
Step 1: Confirm Your Indication
Insurance coverage depends heavily on your diagnosis. GLP-1s are most easily covered when prescribed for:
- Type 2 diabetes (strongest coverage for Ozempic/Mounjaro)
- Obesity (BMI ≥30) with cardiovascular disease (Wegovy/Zepbound in 2025–2026)
- Obesity (BMI ≥27) with a weight-related comorbidity like sleep apnea, hypertension, or high cholesterol
Step 2: Get Prior Authorization
Most insurers require prior authorization (PA) for GLP-1 medications. Your doctor submits medical documentation showing:
- Your diagnosis (T2D, obesity, or qualifying comorbidity)
- Your BMI
- Previous treatments tried (diet, exercise, other medications)
- Clinical need for the specific drug requested
PA approvals typically take 5–14 business days. Ask your doctor’s office to use the insurer’s PA portal for fastest processing.
Step 3: Appeal a Denial
Denial doesn’t mean no. Many initial PA denials are reversed on appeal, especially with:
- A detailed letter of medical necessity from your doctor
- Documentation of failed alternative treatments
- Clinical trial data supporting the indication (your doctor can reference SELECT, SURMOUNT trials)
Request an expedited appeal if waiting would harm your health. You have the right to an external appeal with an independent reviewer.
Manufacturer Savings Programs (For When Insurance Won’t Cover)
If insurance doesn’t cover your GLP-1, manufacturer savings cards can dramatically reduce cost:
- Ozempic Savings Offer (Novo Nordisk): As low as $25/month for eligible commercially insured patients. Uninsured may qualify for patient assistance.
- Wegovy Savings Card: As low as $0/month for the first 3 months for eligible patients, then reduced copay.
- Mounjaro Savings Card (Lilly): As low as $25/month for eligible commercially insured patients.
- Zepbound Savings Card (Lilly): As low as $25/month for eligible commercially insured patients. Lilly also offers Zepbound vials at $399–$549/month directly through LillyDirect for uninsured.
Important: Savings cards do NOT work with Medicare, Medicaid, or any federally funded insurance. They’re for commercially insured patients only. For more details, see our Mounjaro and Zepbound discounts.
Medicare Coverage Updates for GLP-1s in 2026
Medicare’s coverage for weight loss medications has been limited — but is expanding:
- Medicare Part D now covers Wegovy for patients who have both obesity AND established cardiovascular disease (following FDA’s 2024 CV risk reduction approval)
- Ozempic and Mounjaro are covered by Medicare for Type 2 diabetes with standard Part D cost-sharing
- The Treat and Reduce Obesity Act has been reintroduced in Congress to expand Medicare coverage for all obesity medications — not yet law as of 2026
Frequently Asked Questions
What if my employer plan doesn’t cover GLP-1s?
Ask HR if the plan can be amended during the next contract period — employer plans have flexibility that individual plans don’t. In the meantime, use manufacturer savings cards if you have commercial insurance, or explore telehealth platforms that offer compounded semaglutide at lower cost (check current FDA rules on compounding availability).
Can my doctor prescribe Ozempic for weight loss and have insurance cover it?
Generally no — insurers pay based on diagnosis code, not prescription. If your primary diagnosis is obesity without T2D, they typically won’t cover Ozempic (which is approved for T2D, not obesity). Wegovy is the approved product for weight management. Some plans do cover off-label Ozempic for obesity — check your specific plan documents.
Does GoodRx work for GLP-1 medications?
GoodRx discounts for brand-name GLP-1s are minimal compared to list price — typically saving $50–$100 on a $1,000+ medication. Manufacturer savings cards almost always beat GoodRx for commercially insured patients. GoodRx is more useful if you’re paying out of pocket and the manufacturer card doesn’t apply (e.g., you have Medicare).
📚 Related Reading
📖 Further Reading
Considering GLP-1 Medication?
Check eligibility for compounded semaglutide — the affordable alternative to brand-name Ozempic starting from $149/month. No insurance required.
Take the Free Eligibility Quiz →
Sponsored | Affiliate link | Not available in all states
Sources & References
- U.S. Food and Drug Administration (FDA) – Drug Approvals and Databases
- National Institutes of Health (NIH) – PubMed Medical Literature
- American Diabetes Association – Medication & Therapies
- Novo Nordisk – Clinical Research Data
- Eli Lilly – Medical Information
This content is regularly reviewed and updated to reflect the latest medical research and FDA guidance.